|
|
|
|
Cutaneous T-Cell Lymphoma
Gloucester Pharmaceuticals Announces Expansion of Pivotal Trial of ... 14 Mar 2006
Genetic Engineering News, ...company, today announced that it has expanded its multinational clinical trial of depsipeptide (FK228) for the treatment of cutaneous T-cell lymphoma (CTCL) to ...
BioCryst Initiates Intravenous Peramivir Phase I Clinical Trial Mar 9, 2006
International News Service, Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL), a Phase II trial in ...
A CANCER DRUG’S BIG PRICE RISE IS CAUSE FOR CONCERN Mar 12, 2006
Amherst Times.com, For decades, it has been blended into an ointment by pharmacists and used as a topical treatment for a cancer called cutaneous T-cell lymphoma, a form of ...
Genmab Announces Year End 2005 Financial Results Feb 16, 2006
PR Newswire UK (press release), USD 15 million) from the end of 2004. HuMax-CD4 - Demonstrated long lasting responses in Phase II cutaneous T-cell lymphoma (CTCL) study. ...
Genmab Announces Year End 2005 Financial Results Feb 16, 2006
PR Newswire (press release), ...a number of business and scientific milestones, as follows: HuMax-CD4 * Demonstrated long lasting responses in Phase II cutaneous T-cell lymphoma (CTCL) study. ...
Gloucester Pharmaceuticals Reports on Phase 2 Clinical Study ... Mar 1, 2006
Business Wire (press release), ...the Food and Drug Administration and European Orphan Drug designation by the EMEA as a monotherapy for the treatment of cutaneous T-cell lymphoma in patients ...
SCIREX Appoints Dr. Susan Shelby Executive Director, Clinical ... Feb 15, 2006
Pharmaceutical Processing, Her clinical research experience in the areas of oncology and hematology includes cutaneous T-cell lymphoma, advanced non-small cell lung cancer, renal cancer ...
BioCryst Receives FDA Fast Track Designation for Peramivir Jan 17, 2006
Biotech Intelligence (press release), Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL), a Phase II trial in ...
Vitamin A analog bexarotene fights lung cancer Jan 17, 2006
Food Consumer, Bexarotene is already used to treat a form of cancer known as cutaneous T-cell lymphoma (CTCL). It acts to interfere with the growth of tumor cells. ...
BioCryst Initiates Intravenous Phase I/II Clinical Trial of ... Dec 22, 2005
PR Newswire (press release), ...for treatment of T-cell malignancies, and has been designated an "Orphan Drug" for broader indications, including cutaneous T-cell lymphoma (CTCL), chronic ...
Biotech Racks Up Another Impressive Quarter to Close Year in ... Jan 3, 2006
PR Newswire (press release), Myocet, a cardio-protective chemotherapy agent used to treat late-stage breast cancer; Targretin, a treatment for cutaneous T-cell lymphoma; and Abelcet, an ...
Biovest International Announces Addition to Senior Management Team Jan 4, 2006
Genetic Engineering News, At Seragen she played a key role in bringing a biologic product (Ontak, for cutaneous T-cell lymphoma) from development through commercialization. ...
A cancer-free Christmas Dec 24, 2005
The News-Press, Jacksonville. Doctors diagnosed her with stage IV Cutaneous T-cell lymphoma — a cancer that causes lesions, blisters and chronic itching. ...
BioCryst Announces Early Termination of Hart-Scott-Rodino Waiting ... 21 Dec 2005
PharmaLive.com (press release), ...patients with T-cell leukemia, Phase I trial of BCX-4208, the Phase I trial of Fodosine(TM) for treatment of patients with cutaneous T- cell lymphoma and the ...
BioCryst Announces $30.0 Million Common Stock Offering to ... Dec 15, 2005
PR Newswire (press release), Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL) and a Phase II trial in ...
Phase II Study Demonstrates that ONTAK(R) Benefits Patients with ... Dec 14, 2005
Business Wire (press release), ...owned subsidiary of Ligand, marketing approval for ONTAK for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, whose malignant ...
Genmab Announces Responses With HuMax-CD4(TM) in Non-Cutaneous T ... Dec 12, 2005
Yahoo! News (press release) News) announced today preliminary results in the Phase II study using HuMax-CD4(TM) to treat patients with refractory or relapsed non-cutaneous T-cell lymphoma ...
BioCryst Announces Presentation of Fodosine(TM) Data During the ... Dec 12, 2005
Yahoo! News (press release) Data from a third study, "Phase I/II Study of Oral Fodosine(TM), a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma (CTCL) Patients" by Dr. Madeleine ...
Genmab Announces Responses with HuMax-CD4 in Non-Cutaneous T-Cell ... Dec 12, 2005
PharmaLive.com (press release), GEN) announced today preliminary results in the Phase II study using HuMax-CD4 TM to treat patients with refractory or relapsed non-cutaneous T-cell lymphoma. ...
(Euronext Paris) - Memscap : Therakos selects Memscap for cell ... Dec 16, 2005
Euronext (persbericht), Therakos’ pionneering technology that enables treatment of cutaneous T-cell lymphoma (CTCL), ie skin cancer, is based on photopheresis therapy. ...
Transgene releases positive Phase I/II data of TG1042 (Ad-IFNg) ... Dec 11, 2005
Canada NewsWire (press release), Out of the 26 patients with cutaneous T-cell lymphoma (CTCL) 46% responded (six CR and six PR), and 100% of the five patients with cutaneous B-cell lymphoma ...
Merck's Sneak Attack Dec 15, 2005
Forbes ...of the HIV virus to mix its genetic information with that of a patient's cells, and Merck's first cancer drug, targeted against cutaneous T-cell lymphoma.
Cephalon expected to buy British drugmaker Dec 6, 2005
philly.com, ...three key cancer products: Myocet, a chemotherapy treatment used in late-stage breast cancer; Targretin, a medicine for cutaneous T-cell lymphoma; and Abelcet ...
BioCryst Announces Publication of Abstracts on Fodosine(TM) and ... Nov 17, 2005
PR Newswire (press release), ..."Phase I/II Study of Oral Fodosine(TM), a PNP Inhibitor in Refractory Cutaneous T-Cell Lymphoma Patients" (M. Duvic et al.) will be presented by Dr. Madeleine ...
BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal Nov 30, 2005
BioWorld Online (subscription), Atop its pipeline beyond BCX-4208 is Fodosine, which is in a Phase IIa study for T-cell lymphoma and Phase I for cutaneous T-cell lymphoma. ...
(PRN) - Australia Orders ITT's SINCGARS for Interoperability ... ... Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Genmab Announces Responses With HuMax-CD4(TM) in Non-Cutaneous T-Cell Lymphoma ... [+. PRN) - Containment Technologies Group, Inc. ...
Making drugs on slim budget Dec 5, 2005
philly.com, Yaupon's most advanced compound, Clearazide, is a topical ointment using a generic intravenous chemotherapy drug to treat cutaneous T-cell lymphoma, a difficult ...
UPDATE 1-Cephalon to buy Zeneus for $360 mln as eyes Europe Dec 6, 2005
Reuters They include Myocet, a chemotherapy drug used in breast cancer, Targretin, a treatment for cutaneous T-cell lymphoma, and Abelcet, an anti-fungal treatment. ...
Cephalon to pay $360M for Zeneus Dec 6, 2005
MarketWatch ...include Myocet, a cardio-protective chemotherapy agent used to treat late-stage breast cancer; Targretin, which treats cutaneous T-cell lymphoma; and Abelcet ...
Biomedical M&A Heats Up Dec 6, 2005
Red Herring, Other products include Targretin, a treatment for cutaneous T-cell lymphoma, where certain cells of the lymph system become cancerous; and Abelcet, an anti ...
Celgene Seen As 'Key Portfolio Holding' In Biotech Dec 12, 2005
Forbes ...of Phase III data for Revlimid's results in multiple myeloma, as well as previews of presentations on chronic leukemia and cutaneous T-cell lymphoma, both of ...
Cephalon, Inc. Announces Agreement to Acquire Zeneus Holdings ... Dec 5, 2005
PR Newswire UK (press release), ...a cardio-protective chemotherapy agent used to treat late-stage breast cancer; Targretin(R) (bexarotene), a treatment for cutaneous T-cell lymphoma; and Abelcet ...
Cephalon buys English pharma firm Dec 6, 2005
Philadelphia Business Journal, Myocet, a cardio-protective chemotherapy agent used to treat late-stage breast cancer; Targretin, a treatment for cutaneous T-cell lymphoma; and Abelcet, an ...
Gloucester Pharmaceuticals Announces Presentations of Depsipeptide ... Dec 1, 2005
Business Wire (press release), ...of the National Cancer Institute (NCI) will present Abstract #231 "Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled in a ...
Resurgent BioCryst Does It Again Nov 30, 2005
TheStreet.com Fodosine is meant to treat late-stage cancer of the T-cells, as well as cutaneous T-cell lymphoma, a type of blood cancer that affects the skin, in patients ...
Early Phase 1 Trial of Decitabine Suggests a Low Dose May Reduce ... Nov 18, 2005
DG News Results so far show no dose-limiting toxicity in cohort 1, and a heavily pretreated patient with cutaneous T-cell lymphoma experienced a minor response, Dr ...
Allogeneic Stem Cell Transplants Effective for Refractory ... Sep 6, 2005
...effect.[3],[4],[5] Researchers from Northwestern University reported long-term remissions in two of three patients with cutaneous T-cell lymphoma with one ... Cancer Consultants (press release),
BioCryst to Present at the Bear Stearns 18th Annual Healthcare ... Sep 7, 2005
Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL) and a Phase II trial in ... Yahoo! News (press release)
Serono and Genmab Announce Global Development and ... Aug 17, 2005
HuMax-CD4 Currently in Phase III Clinical Trial for Cutaneous T-Cell Lymphoma and Phase II Clinical Trial for Non-Cutaneous T-Cell Lymphoma GENEVA, Switzerland ... PR Newswire (press release),
Serono and Genmab Announce Global Development and ... Aug 17, 2005
It is currently being evaluated in a pivotal Phase III clinical trial for cutaneous T-cell lymphoma (CTCL) under the US Food and Drug Administration's Special ... Yahoo News (press release)
Genmab, Serono Sign Potential $215M Deal For HuMax-CD4 Aug 18, 2005
...company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma. ... BioWorld Online (subscription),
BioCryst starts phase I pharmacokinetic study of Fodosine Aug 9, 2005
T-cell mediated cancers, and has been designated an orphan drug for several indications, including T-cell leukemia, cutaneous T-cell lymphoma (CTCL), chronic ... Pharmaceutical Business Review
Gloucester Pharmaceuticals Strengthens Management Team in Key ... Aug 25, 2005
...and marketing will be invaluable as depsipeptide continues to make progress in a pivotal clinical trial of patients with cutaneous T-cell lymphoma as well as ... PharmaLive.com (press release),
Energy stocks weigh on Europe, RBS up on China deal Aug 18, 2005
...sales milestones to Denmark's Genmab to develop and commercialize HuMax-CD4, a drug under a Phase III clinical trial for cutaneous T-cell lymphoma that has ... Investor's Business Daily (subscription)
Ligand Gets FDA Nod For 2nd Avinza Manufacturing Site Aug 18, 2005
Targretin, approved by the FDA back in December 1999, is used to treat skin problems from a disease called cutaneous T-cell lymphoma. ... SanDiego.com,
When punishment is the crime Aug 22, 2005
...rubella vaccine ... ". - A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. -- A new initiative ... Town Hall,
MP vows to carry on despite cancer Aug 20, 2005
...diagnosed with cancer. Cutaneous T-cell lymphoma is a rare and incurable cancer that affects the skin and immune system. Mr Quigley ... ABC Online,
Coley IPO, Placement Brings In $106M For TLR Drug Discovery Aug 11, 2005
Pfizer worldwide rights to ProMune, a TLR9 agonist that is in Phase II trials for non-small-cell lung cancer, malignant melanoma and cutaneous T-cell lymphoma. ... BioWorld Online (subscription),
When punishment is the crime Aug 23, 2005
...mumps, rubella vaccine. . . .". A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. Washington Times,
Allogeneic Stem Cell Transplants Effective for Refractory ... -- Sep 6, 2005
...effect.[3],[4],[5] Researchers from Northwestern University reported long-term remissions in two of three patients with cutaneous T-cell lymphoma with one ... / Cancer Consultants (press release),
BioCryst to Present at the Bear Stearns 18th Annual Healthcare ... -- Sep 7, 2005
Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL) and a Phase II trial in ... / Yahoo! News (press release)
Serono and Genmab Announce Global Development and ... -- Aug 17, 2005
HuMax-CD4 Currently in Phase III Clinical Trial for Cutaneous T-Cell Lymphoma and Phase II Clinical Trial for Non-Cutaneous T-Cell Lymphoma GENEVA, Switzerland ... / PR Newswire (press release),
Serono and Genmab Announce Global Development and ... -- Aug 17, 2005
It is currently being evaluated in a pivotal Phase III clinical trial for cutaneous T-cell lymphoma (CTCL) under the US Food and Drug Administration's Special ... / Yahoo News (press release)
Genmab, Serono Sign Potential $215M Deal For HuMax-CD4 -- Aug 18, 2005
...company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma. ... / BioWorld Online (subscription),
Gloucester Pharmaceuticals Strengthens Management Team in Key ... -- Aug 25, 2005
...and marketing will be invaluable as depsipeptide continues to make progress in a pivotal clinical trial of patients with cutaneous T-cell lymphoma as well as ... / PharmaLive.com (press release),
Energy stocks weigh on Europe, RBS up on China deal -- Aug 18, 2005
...sales milestones to Denmark's Genmab to develop and commercialize HuMax-CD4, a drug under a Phase III clinical trial for cutaneous T-cell lymphoma that has ... / Investor's Business Daily (subscription)
Ligand Gets FDA Nod For 2nd Avinza Manufacturing Site -- Aug 18, 2005
Targretin, approved by the FDA back in December 1999, is used to treat skin problems from a disease called cutaneous T-cell lymphoma. ... / SanDiego.com,
When punishment is the crime -- Aug 22, 2005
...rubella vaccine ... ". - A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. -- A new initiative ... / Town Hall,
MP vows to carry on despite cancer -- Aug 20, 2005
...diagnosed with cancer. Cutaneous T-cell lymphoma is a rare and incurable cancer that affects the skin and immune system. Mr Quigley ... / ABC Online,
When punishment is the crime -- Aug 23, 2005
...mumps, rubella vaccine. . . .". A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. / Washington Times,
Allogeneic Stem Cell Transplants Effective for Refractory ... Sep 6, 2005
...effect.[3],[4],[5] Researchers from Northwestern University reported long-term remissions in two of three patients with cutaneous T-cell lymphoma with one ... Cancer Consultants (press release),
BioCryst to Present at the Bear Stearns 18th Annual Healthcare ... Sep 7, 2005
Additionally, Fodosine(TM) is currently being studied in a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL) and a Phase II trial in ... Yahoo! News (press release)
Serono and Genmab Announce Global Development and ... Aug 17, 2005
HuMax-CD4 Currently in Phase III Clinical Trial for Cutaneous T-Cell Lymphoma and Phase II Clinical Trial for Non-Cutaneous T-Cell Lymphoma GENEVA, Switzerland ... PR Newswire (press release),
Serono and Genmab Announce Global Development and ... Aug 17, 2005
It is currently being evaluated in a pivotal Phase III clinical trial for cutaneous T-cell lymphoma (CTCL) under the US Food and Drug Administration's Special ... Yahoo News (press release)
Genmab, Serono Sign Potential $215M Deal For HuMax-CD4 Aug 18, 2005
...company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma. ... BioWorld Online (subscription),
BioCryst starts phase I pharmacokinetic study of Fodosine Aug 9, 2005
T-cell mediated cancers, and has been designated an orphan drug for several indications, including T-cell leukemia, cutaneous T-cell lymphoma (CTCL), chronic ... Pharmaceutical Business Review
Gloucester Pharmaceuticals Strengthens Management Team in Key ... Aug 25, 2005
...and marketing will be invaluable as depsipeptide continues to make progress in a pivotal clinical trial of patients with cutaneous T-cell lymphoma as well as ... PharmaLive.com (press release),
Energy stocks weigh on Europe, RBS up on China deal Aug 18, 2005
...sales milestones to Denmark's Genmab to develop and commercialize HuMax-CD4, a drug under a Phase III clinical trial for cutaneous T-cell lymphoma that has ... Investor's Business Daily (subscription)
Ligand Gets FDA Nod For 2nd Avinza Manufacturing Site Aug 18, 2005
Targretin, approved by the FDA back in December 1999, is used to treat skin problems from a disease called cutaneous T-cell lymphoma. ... SanDiego.com,
When punishment is the crime Aug 22, 2005
...rubella vaccine ... ". - A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. -- A new initiative ... Town Hall,
MP vows to carry on despite cancer Aug 20, 2005
...diagnosed with cancer. Cutaneous T-cell lymphoma is a rare and incurable cancer that affects the skin and immune system. Mr Quigley ... ABC Online,
Coley IPO, Placement Brings In $106M For TLR Drug Discovery Aug 11, 2005
Pfizer worldwide rights to ProMune, a TLR9 agonist that is in Phase II trials for non-small-cell lung cancer, malignant melanoma and cutaneous T-cell lymphoma. ... BioWorld Online (subscription),
When punishment is the crime Aug 23, 2005
...mumps, rubella vaccine. . . .". A Phase II cancer compound for treating cutaneous T-cell lymphoma," now in clinical trials. Washington Times,
FDA Approves New Fill/Finish Facility for ONTAK(R); Includes ... -- Jul 5, 2005
...owned subsidiary of Ligand, marketing approval for ONTAK for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose ... / Business Wire (press release),
Investigators Present Targretin(R) Data at World Lung Cancer ... -- Jul 5, 2005
Targretin is a selective retinoid X receptor (RXR) modulator with proven efficacy as monotherapy in the treatment of cutaneous T-cell lymphoma (CTCL). ... / Genetic Engineering News,
BioCryst Receives FDA Fast Track Status for Fodosine(TM) in the ... -- Jun 20, 2005
The drug is currently in a Phase IIa trial for patients with T-cell leukemia and a Phase I trial with an oral formulation in cutaneous T-cell lymphoma (CTCL). ... / RedNova.com,
ProMuneâ„¢ Immunotherapy Promising for Non-Small Cell Lung Cancer -- Jun 16, 2005
There have been promising results with intralesional injections in basal cell carcinoma, cutaneous T-cell lymphoma and melanoma. ... / Cancer Consultants (press release),
Discovery Blocks Breast Cancer Growth, Stimulates Immunity -- Jun 9, 2005
...is commercially available and currently approved for use by the US Food and Drug Administration (FDA) to treat a different disease, cutaneous T-cell lymphoma. ... / Newswise (press release)
Genmab Acquires Worldwide Rights For HuMax-CD4 -- Jun 30, 2005
...the CD4 antigen, including HuMax-CD4(TM), a fully human antibody that Genmab currently has in Phase III clinical studies to treat cutaneous T-cell lymphoma. ... / Yahoo News (press release)
Genmab's Buy Of Rights To HuMax-CD4 Neutral -- Jun 30, 2005
Although HuMax-CD4 is in phase 3 trials for the treatment of cutaneous T-cell lymphoma, there is no guarantee it will be approved for marketing. ... / New Ratings
SRI International Celebrates 50 Years of Drug Discovery and ... -- Jun 20, 2005
Bexarotene was discovered at SRI and is marketed for cutaneous T-cell lymphoma. SRI has more than a dozen cancer drugs in R&D, including: ... / Business Wire (press release),
You can call 'em lung-cancer bloodhounds -- Jun 15, 2005
Already, Showe’s laboratory has identified very early cases of a rare cancer called cutaneous T-cell lymphoma, and is working to apply similar processes to ... / Philadelphia Daily News,
SRI International Celebrates 50 Years of Drug Discovery and ... -- Jun 20, 2005
Division since its inception. Bexarotene was discovered at SRI and is marketed for cutaneous T-cell lymphoma. SRI has more than ... / PharmaLive.com (press release),
BioCryst Pharmaceuticals Successfully Completes Phase I Trial With ... -- Mar 15, 2005
...currently in a Phase IIa trial for patients with T-cell malignancies and a Phase I trial with oral forodesine hydrochloride in cutaneous T-cell lymphoma (CTCL ... / PR Newswire (press release)
Rates climb on short-term bills -- Mar 15, 2005
The patents will now be assigned to Ligand. Targretin is approved by the US Food and Drug Administration to treat cutaneous t-cell lymphoma. ... / San Diego Union Tribune
Gloucester Pharmaceuticals Initiates Pivotal Trial with FK228 in ... -- Mar 1, 2005
...it has initiated a pivotal trial of its novel histone deacetylase (HDAC) inhibitor, FK228 (depsipeptide), for the treatment of cutaneous T-cell lymphoma (CTCL ... / PharmaLive.com (press release),
Ligand and SRI/Burnham Agree to Settle Patent Interference on ... -- Mar 14, 2005
In December 1999, the FDA approved Targretin capsules for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory ... / PharmaLive.com (press release),
Gloucester begins pivotal lymphoma trial -- Mar 2, 2005
Private cancer therapeutics developer Gloucester Pharmaceuticals has initiated a pivotal trial of FK228 in cutaneous T-cell lymphoma, following the receipt of ... / Pharmaceutical Business Review
Molecular triggers in malignant lymphoma -- Feb 28, 2005
In a study published in the journal Blood, Yale scientists identify the molecular triggers that stimulate Cutaneous T Cell Lymphoma (CTCL) cells to clonally ... / myDNA.com,
Gloucester Pharmaceuticals Appoints Nicholas Vrolijk, PhD. Vice ... -- Mar 10, 2005
...and Orphan Drug designations by the US Food and Drug Administration (FDA) for FK228 as a monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) in ... / Business Wire (press release),
HuMax-CD4 Continues to Show Long Lasting Responses in T-Cell ... -- Feb 18, 2005
...response data from one of its HuMax-CD4 (zanolimumab) Phase II studies treating patients with mycosis fungoides (MF) a type of cutaneous T-cell lymphoma (CTCL ... / PharmaLive.com (press release),
BioCryst to Raise Approximately $23.9 Million Through Sale of ... -- Feb 17, 2005
...status by the US Food and Drug Administration for three indications: T-cell non-Hodgkin’s lymphoma, including cutaneous T-cell lymphoma; chronic lymphocytic ... / mysan.de (Pressemitteilung),
Gloucester Pharma kicks off human test of lymphoma drug -- Mar 1, 2005
...company said the US Food and Drug Administration has approved the trial to use its histone deacetylase inhibitor FK228 to treat cutaneous T-cell lymphoma. ... / Boston Business Journal,
Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 ... -- Feb 22, 2005
...long-lasting. Ad-IFNgamma is currently in Phase I/II clinical trial in primary cutaneous T-cell lymphoma (CTCL). Interim results ... / Yahoo News (press release)
Transgene: New Strategy in Therapeutic Vaccines, MVA-Muc1-IL2 ... -- Feb 22, 2005
...product: accelerated development in cutaneous lymphoma Ad-IFNgamma is currently in Phase I/II clinical trial in primary cutaneous T-cell lymphoma (CTCL). ... / PR Newswire (press release)
Genmab antibody shows lasting responses in skin cancer -- Feb 21, 2005
...latest set of duration of response data is very encouraging and indicates that HuMax-CD4 may be effective in treating cutaneous T-cell lymphoma (CTCL) patients ... / Pharmaceutical Business Review
Cutaneous T-Cell lymphoma (CTCL) is a class of non-Hodgkin's lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin's lymphomas (which are generally B-cell related), CTCL is caused by a mutation of T cells. The malignant T cells in the body are pushed to the surface of the skin in a biological process used to rid the body of offending material, causing various lesions to appear on the skin. These lesions change shape as the disease progresses, typically beginning as what appears to be a rash and eventually forming plaques and tumors before metastatizing to other parts of the body.
Though there are many types of CTCL and presentation can vary from individual to individual, there are two main forms: mycosis fungoides (MF) and Sézary syndrome (SS). There is some dispute over whether SS is an advanced form of MF or a different type of CTCL entirely -- in either case, the prognosis for SS patients is substantially poorer than for those of MF.
There is no cure for CTCL, but there are a variety of treatment options available and most (about 90%) of CTCL patients are able to live relatively normal lives without serious, health-compromising complications.
|
|
|
